...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Once-weekly epoetin beta (30,000 IU) in anemic patients with lung cancer receiving chemotherapy.
【24h】

Once-weekly epoetin beta (30,000 IU) in anemic patients with lung cancer receiving chemotherapy.

机译：每周重组β(30000 IU)贫血肺癌患者接受化疗。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Anemia occurs frequently in patients with lung cancer receiving chemotherapy and has a negative impact on quality of life (QoL). Erythropoietic proteins effectively increase hemoglobin (Hb) levels, reduce transfusion requirements and improve QoL in anemic patients with a range of malignancies. This prospective, observational study evaluated epoetin beta 30,000 IU once weekly in patients with lung cancer in a real-life, clinical-practice setting. Forty patients (72.5% with NSCLC and 27.5% with SCLC) were treated with epoetin beta during any cycle of chemotherapy when Hb decreased to 9 (median 4) weeks. Mean (+/-S.D.) baseline Hb was 10.4+/-1.2 g/dL. Epoetin beta was associated with a rapid increase in Hb levels, with a mean increase of 1.3 g/dL by week4. Most patients (95%) remained transfusion-free throughout the study. Epoetin beta was well tolerated. This early intervention strategy with epoetin beta 30,000 IU once weekly is an effective and well-tolerated therapy for anemia in patients with lung cancer.
机译：贫血患者经常发生在肺癌症接受化疗和消极对生活质量(QoL)的影响。蛋白质有效提高血红蛋白(Hb)水平,减少输血需求和改善贫血患者一系列的生命质量恶性肿瘤。研究评估重组β30000 IU每周在肺癌患者现实生活中,临床实践设置。与SCLC患者与非小细胞肺癌(72.5%和27.5%)治疗期间与重组β周期吗化疗时Hb下降到 9(平均4)周。(+ /南达科他州)基线Hb是10.4 + / - -1.2 g / dL。应用重组β迅速增加Hb水平,平均增加了1.3 g / dLweek4。在整个研究不输血。β是耐受性良好。战略与重组β30000 IU每周1次是一个有效,同时治疗吗贫血患者的肺癌。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号